BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18395138)

  • 1. Early detection of Fabry disease: cardiac cases.
    Weidemann F; Strotmann J
    Clin Ther; 2008; 30 Suppl B():S46. PubMed ID: 18395138
    [No Abstract]   [Full Text] [Related]  

  • 2. The heart in Anderson Fabry disease.
    Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
    Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease in an oligosymptomatic male.
    Altarescu G; Elstein D
    Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
    [No Abstract]   [Full Text] [Related]  

  • 5. The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy.
    Hauser AC; Lorenz M; Sunder-Plassmann G
    J Intern Med; 2004 Jun; 255(6):629-36. PubMed ID: 15147526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
    Wang RY; Abe JT; Cohen AH; Wilcox WR
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatrics: implementing the promise of early intervention for Fabry disease.
    Raas-Rothschild A
    Clin Ther; 2007; 29 Suppl A():S6. PubMed ID: 17580239
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fabry disease: new clinical research--current therapeutic perspectives].
    Beck M
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):215-7. PubMed ID: 12778772
    [No Abstract]   [Full Text] [Related]  

  • 10. Fabry disease--whom to treat and when.
    Mehta A
    Clin Ther; 2008; 30 Suppl B():S43-4. PubMed ID: 18395136
    [No Abstract]   [Full Text] [Related]  

  • 11. [CME. Fabry disease: rare but not to be missed].
    Steinack C; Gaspert A; Kovacs R; Nowak A
    Praxis (Bern 1994); 2015 Jul; 104(14):719-29. PubMed ID: 26135721
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
    Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
    Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
    J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What is new in Fabry disease?].
    Lidove O
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S296-7. PubMed ID: 17964003
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
    Lenders M; Brand E
    J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
    [No Abstract]   [Full Text] [Related]  

  • 16. Anderson-Fabry disease: a protean clinical behavior and a chance diagnosis.
    Amico L; Visconti G; Amato A; Azzolina V; Sessa A; Li Vecchi M
    J Nephrol; 2005; 18(6):770-2. PubMed ID: 16358237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 18. [Consensus for the study and treatment of Fabry disease. GETER Foundation].
    García de Lorenzo A;
    Med Clin (Barc); 2011 Jul; 137(4):178-83. PubMed ID: 21529855
    [No Abstract]   [Full Text] [Related]  

  • 19. Fabrazyme--recombinant protein treatment for Fabry's disease.
    Barngrover D
    J Biotechnol; 2002 May; 95(3):280-2. PubMed ID: 12080957
    [No Abstract]   [Full Text] [Related]  

  • 20. [Neurological manifestations of Fabry disease].
    Mendióroz M; Fernández-Cadenas I; Montaner J
    Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.